{"id":5553,"date":"2023-12-01T10:31:02","date_gmt":"2023-12-01T16:31:02","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5553"},"modified":"2025-06-27T11:27:31","modified_gmt":"2025-06-27T16:27:31","slug":"nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/","title":{"rendered":"Nanoscope Therapeutics anuncia presentaci\u00f3n en el Congreso FLORetina 2023"},"content":{"rendered":"
\n
\n

<\/h1>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span><\/span>,\u00a01 de diciembre de 2023<\/span><\/span> \u2014\u00a0Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en etapa avanzada que desarrolla terapias gen\u00e9ticas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy que Francesco Bandello, MD, FEBO, presentar\u00e1 en la 11th<\/sup>\u00a0Anual\u00a0Congreso FLOREtina<\/span><\/a>\u00a0teniendo lugar desde\u00a0Del 30 de noviembre al 3 de diciembre de 2023<\/span>\u00a0en\u00a0Roma, Italia<\/span>. Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n

T\u00edtulo:<\/b>\u00a0Eficacia y seguridad de la terapia optogen\u00e9tica MCO-010 para la restauraci\u00f3n de la visi\u00f3n en pacientes con p\u00e9rdida grave de la visi\u00f3n debido a retinitis pigmentosa<\/p>\n

Sesi\u00f3n:\u00a0<\/b>Art\u00edculos gratuitos destacados Terapias innovadoras
Fecha de la sesi\u00f3n:<\/b>\u00a02 de diciembre de 2023<\/span>
Tiempo de sesi\u00f3n:<\/b>\u00a010:54 CET
Ubicaci\u00f3n:<\/b>\u00a0Hotel y Centro de Congresos Cavalieri Waldorf Astoria
Presentador:<\/b>\u00a0Francesco Bandello, MD, FEBO, Profesor y Presidente del Departamento de Oftalmolog\u00eda, Universidad Vita-Salute, Ospedale San Raffaele,\u00a0Mil\u00e1n<\/span><\/p>\n

En su presentaci\u00f3n, el profesor Bandello analizar\u00e1 los datos de 12 meses de la fase RESTORE de Nanoscope.\u00a02b<\/span>\u00a0ensayo controlado aleatorio en pacientes con retinitis pigmentosa avanzada.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.<\/b><\/p>\n

Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas independientes del gen que restauran la visi\u00f3n para millones de pacientes ciegos por enfermedades retinianas hereditarias para las que no existe cura. El principal f\u00e1rmaco de la compa\u00f1\u00eda, MCO-010, inform\u00f3 recientemente los resultados preliminares de la fase RESTORE.\u00a02b<\/span>\u00a0ensayo cl\u00ednico multic\u00e9ntrico, aleatorizado, doble enmascarado y controlado de forma simulada en los EE. UU. para la retinitis pigmentosa (NCT04945772<\/a>). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo de fase 2 STARLIGHT de la terapia MCO-010 en pacientes Stargardt (NCT05417126<\/a>\u00a0). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para la atrofia geogr\u00e1fica.<\/p>\n

Contacto de inversores:<\/b>
Socios Argot
212-600-1902
PR@nanostherapeutics.com<\/a><\/p>\n

FUENTE Terap\u00e9utica del Nanoscopio<\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Dec. 1, 2023 \u2014\u00a0Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Francesco Bandello, MD, FEBO, will present at the 11th\u00a0Annual\u00a0FLORetina Congress\u00a0taking place from\u00a0November 30 \u2013 December 3, 2023\u00a0in\u00a0Rome, Italy. Details for the presentation are as follows: Title:\u00a0Efficacy and Safety of […]<\/p>\n","protected":false},"author":6,"featured_media":5554,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5553","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-01T16:31:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:27:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"627\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress\",\"datePublished\":\"2023-12-01T16:31:02+00:00\",\"dateModified\":\"2025-06-27T16:27:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/\"},\"wordCount\":263,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/NSCOPE_LI_FLORetina2023REV.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/\",\"name\":\"Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/NSCOPE_LI_FLORetina2023REV.jpg\",\"datePublished\":\"2023-12-01T16:31:02+00:00\",\"dateModified\":\"2025-06-27T16:27:31+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/NSCOPE_LI_FLORetina2023REV.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2023\\\/12\\\/NSCOPE_LI_FLORetina2023REV.jpg\",\"width\":1200,\"height\":627},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2023\\\/12\\\/01\\\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics anuncia su presentaci\u00f3n en el Congreso FLORetina 2023 - Nanoscope Therapeutics","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2023-12-01T16:31:02+00:00","article_modified_time":"2025-06-27T16:27:31+00:00","og_image":[{"width":1200,"height":627,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress","datePublished":"2023-12-01T16:31:02+00:00","dateModified":"2025-06-27T16:27:31+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/"},"wordCount":263,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/","url":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/","name":"Nanoscope Therapeutics anuncia su presentaci\u00f3n en el Congreso FLORetina 2023 - Nanoscope Therapeutics","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg","datePublished":"2023-12-01T16:31:02+00:00","dateModified":"2025-06-27T16:27:31+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2023\/12\/NSCOPE_LI_FLORetina2023REV.jpg","width":1200,"height":627},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2023\/12\/01\/nanoscope-therapeutics-announces-presentation-at-the-floretina-2023-congress\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5553","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5553"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5553\/revisions"}],"predecessor-version":[{"id":9061,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5553\/revisions\/9061"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5554"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5553"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5553"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5553"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}